BIO

BIO

USD

Bio-Rad Laboratories Inc. Class A Common Stock

$310.960+1.090 (0.352%)

실시간 가격

Healthcare
의료 기기
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$309.870

고가

$316.200

저가

$301.920

거래량

0.18M

기업 기본 정보

시가총액

8.3B

산업

의료 기기

국가

United States

거래 통계

평균 거래량

0.24M

거래소

NYQ

통화

USD

52주 범위

저가 $211.43현재가 $310.960고가 $387.99

AI 분석 리포트

마지막 업데이트: 2025년 11월 1일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

BIO Stock Alert: Bio-Rad Laboratories Shows Short-Term Opportunity Amid Volatility

Breaking Down the Current Picture

Bio-Rad Laboratories (BIO) just wrapped up a wild October. The stock surged from $280 to $340 in three weeks, then crashed 6% in a single day after earnings. Today it’s sitting at $319.55--down from its October peak but still 5% above where it started the month. Let’s cut through the noise.

What the News Tells Us

  • Analyst split is real: Citigroup doubled down with a $375 target (22% upside), while Wells Fargo stayed cautious at $340 despite raising their forecast.
  • Earnings disappointment: The October 29 report triggered immediate selling. No details were provided in the data, but the timing aligns with BIO’s sharp 6% drop that day.
  • Sentiment is neutral overall--bullish upgrades are fighting against weak fundamentals.

Price Action Decoded

Here’s what the chart whispers:

  • The $340 wall matters: BIO tested this level twice in late October (Oct 21 and 24) but couldn’t break through. Each time, heavy selling followed.
  • Support at $318.50 is make-or-break: Yesterday’s close ($319.55) barely held above this technical floor. Volume spiked to 510K shares on the drop (Oct 29)--more than double its average.
  • That "bullish" MACD crossover? It happened at $322 on Oct 15, but the stock stalled anyway. Technicals alone won’t drive this move.

Where It’s Headed Next

Short-term signals are messy: ✅ Bullish spark: Current price hovering at the Bollinger Band lower limit ($318.51) often triggers bounces. ⚠️ Red flags: Negative ROE (-9.5%) and sky-high debt (20.7 D/E ratio) scream "fundamental trouble." 🔮 AI’s mixed forecast: +0.5% tomorrow → -0.3% the next day → +0.9% on day 3. Translation: Choppy trading ahead.

Actionable Guidance

For traders only--this isn’t a long-term hold.

Entry Strategy

  • Best window: $317-$319.50 (yesterday’s low was $315.10--don’t chase below that).
  • Why now?: Extreme volume on the drop (510K shares) suggests panic selling washed out.
  • Critical trigger: Wait for a 15-minute candle closing above $322 to confirm reversal.

Exit Plan

  • Take profit: $342 (Wells Fargo’s target). Anything beyond $345 faces serious resistance.
  • Stop loss: $314.50 (1.5% below yesterday’s low). Do not move this lower.
  • Time limit: Max 10 trading days. This setup dies if the $318 support breaks.

Who Should Skip This

  • Long-term investors: Debt and negative ROE are structural issues.
  • Risk-averse traders: The 6% single-day swing shows BIO isn’t for the faint of heart.
  • Anyone needing stability: This stock moves on earnings whispers and analyst notes--not steady growth.

Bottom Line

BIO is a short-term scalp, not a portfolio cornerstone. The $318 support level is the fulcrum. If it holds with volume

관련 뉴스

Analyst Upgrades

Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories with a Buy and raises the price target from $350 to $375.

더 보기
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories with a Equal-Weight and raises the price target from $265 to $340.

더 보기
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
BusinessWire

Bio-Rad Reports Third-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third

더 보기
Bio-Rad Reports Third-Quarter 2025 Financial Results

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 11월 5일 오전 03:27

약세중립강세

66.2% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
보통
트레이딩 가이드

진입점

$308.48

익절

$317.74

손절

$280.36

핵심 요소

PDI 11.1이(가) ADX 16.5과 함께 MDI 10.1 위에 있어 강세 추세를 시사합니다.
현재 가격이 지지선($309.58)에 매우 근접하여 강력한 매수 기회를 시사합니다.
거래량은 평균(3,528)의 5.4배로 극도로 강력한 매수 압력을 나타냅니다.
MACD -0.0968이(가) 신호선 -0.3920 위에 있어 강세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기